Oncologix Tech (OCLG) Stock Statistics & Valuation Metrics
Total Valuation
Oncologix Tech has a market cap or net worth of $1,662.00. The enterprise value is $73.66B.
- Market Cap
- $1,662.00
- Enterprise Value
- $73.66B
Share Statistics
Oncologix Tech has 1,662,469,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,662,469,200
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Oncologix Tech’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is 106.15%.
- Return on Equity (ROE)
- 0.40
- Return on Assets (ROA)
- -1.59
- Return on Invested Capital (ROIC)
- 106.15%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 14.92K
- Profits Per Employee
- -12.41K
- Employee Count
- 191
- Asset Turnover
- 1.91
- Inventory Turnover
- 759.67
Valuation Ratios
The current PE Ratio of Oncologix Tech is -0.03. Oncologix Tech’s PEG ratio is -0.00.
- PE Ratio
- -0.03
- PS Ratio
- 0.03
- PB Ratio
- 0.04
- Price to FCF
- -2.93
- Price to Operating Cash Flow
- -3.04
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Oncologix Tech had revenue of 2.85M and earned -2.37M in profits. Earnings per share was -0.00.
- Revenue
- 2.85M
- Gross Profit
- 571.56K
- Operating Income
- -865.00K
- Pretax Income
- -2.37M
- Net Income
- -2.37M
- EBITDA
- -1.11M
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -18.77K and capital expenditures 0, giving a free cash flow of -18.77K billion.
- Operating Cash Flow
- -18.77K
- Free Cash Flow
- -18.77K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
Oncologix Tech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -34.10%
- Earnings Yield
- -3218.77%
Stock Price Statistics
- Beta
- -9.25
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
Oncologix Tech as a current ratio of 0.03, with Debt / Equity ratio of -86.35%
- Current Ratio
- 0.03
- Quick Ratio
- 0.03
- Debt to Market Cap
- 23.33
- Net Debt to EBITDA
- -4.62
- Interest Coverage Ratio
- -0.69
Taxes
In the past 12 months, Oncologix Tech has paid 3 in taxes.
- Income Tax
- 3
- Effective Tax Rate
- -0.00
Enterprise Valuation
Oncologix Tech EV to EBITDA ratio is -0.07, with an EV/FCF ratio of -2.93.
- EV to Sales
- 0.03
- EV to EBITDA
- -0.07
- EV to Free Cash Flow
- -2.93
- EV to Operating Cash Flow
- -3.04
Balance Sheet
Oncologix Tech has $4,850.00 in cash and marketable securities with $23.62K in debt, giving a net cash position of -$18.77K billion.
- Cash & Marketable Securities
- $4,850.00
- Total Debt
- $23.62K
- Net Cash
- -$18.77K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- $0.00
Margins
Gross margin is 20.05%, with operating margin of -30.35%, and net profit margin of -83.19%.
- Gross Margin
- 20.05%
- Operating Margin
- -30.35%
- Pretax Margin
- -83.19%
- Net Profit Margin
- -83.19%
- EBITDA Margin
- -38.95%
- EBIT Margin
- -39.47%
Analyst Forecast
The average price target for Oncologix Tech is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
